BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ONCOlog Spins-off DrugLog into New Company


4/27/2007 9:24:05 AM

STOCKHOLM, Sweden--(BUSINESS WIRE)--LinkMed's (STO:LMED) portfolio company ONCOlog Medical is spinning off a part of its operations into a new portfolio company, Pharmacolog i Uppsala AB. The new company will develop systems to control the contents and concentration of pharmaceutical drugs and is taking over the rights to the DrugLog product.

DrugLog is a system that controls the content and concentration of liquid medicine, such as chemotherapy, for example. Today, many such medicines are often prepared manually, usually by the hospital pharmacy or respective ward. It is not unusual that errors occur in dosage preparation, the effect of which can be fatal for the patient. This is a problem that is being addressed by public authorities, caregivers, labor unions and patient organizations.

"DrugLog can markedly improve patient safety within cancer care, something that is in unanimous demand throughout the industry. By creating a separate company for DrugLog, the project will be given the appropriate level of priority, with a higher pace of development," says LinkMed's CEO Ingemar Lagerlof.

Pharmacolog, which will become a new LinkMed portfolio company, will initially further develop DrugLog to prepare it for out-licensing. A patent is pending for the product in the U.S., Europe and Japan. LinkMed's senior venture manager Lars Martin will become chairman of the new company, while ONCOlog Medical's Head of Technology Kjell Westerlund will become part time CEO. The company is currently under formation.

Following the spin off, ONCOlog Medical will focus exclusively on systems and products for various types of radiotherapy. LinkMed's has a 48 percent ownership stake in both ONCOlog Medical and Pharmacolog i Uppsala.

LinkMed, in collaboration with innovators develops new life science companies. By contributing entrepreneurship and capital, LinkMed has created a portfolio of ten companies, six in biotechnology and four in medical technology. The LinkMed share is listed on the Stockholm Stock Exchange and the company's largest owners are FastPartner, Koncentra Holding, Mannerson Fastigheter and the founder Ingemar Lagerlof. See linkmed.se for more information.

LinkMed, in collaboration with innovators develops new life science companies. By contributing entrepreneurship and capital, LinkMed has created a portfolio of ten companies, six in biotechnology and four in medical technology. The LinkMed share is listed on the Stockholm Stock Exchange and the company's largest owners are FastPartner, Koncentra Holding, Mannerson Fastigheter and the founder Ingemar Lagerlof. See linkmed.se for more information.

This information was brought to you by Cision http://newsroom.cision.com

Contact: LinkMed. Ingemar Lagerlof, CEO, +46 8 508 939 93

Source: LinkMed

Read at BioSpace.com

ONCOlog
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES